SCHEMBL19432006

SCHEMBL19432006

CNCCN(C)Cc1c[nH]nc1-c1cc(CC(F)(F)F)cc(OCCOC)c1

nearest known ligand 0.33

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ PRMT1 Q99873 15/20 0.33
▸ PRMT6 Q96LA8 2/20 0.33
▸ CARM1 Q86X55 10/20 0.32
▸ MAP4K4 O95819 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16124050 0.89 PRMT1 (0.38) PRMT1PRMT6CARM1
SCHEMBL19432084 0.87 PRMT1 (0.33) PRMT1PRMT6CARM1
SCHEMBL19432205 0.87 PRMT1 (0.42) PRMT1PRMT6CARM1
SCHEMBL19432093 0.86 PRMT1 (0.33) PRMT1CARM1
SCHEMBL19432245 0.84 PRMT1 (0.32) PRMT1PRMT6CARM1
SCHEMBL16129112 0.84 PRMT1 (0.37) PRMT1PRMT6CARM1
SCHEMBL19432327 0.83 PRMT1 (0.32) PRMT1PRMT6CARM1
SCHEMBL19432320 0.81 PRMT1 (0.45) PRMT1PRMT6CARM1
SCHEMBL17758389 0.81 PRMT1 (0.45) PRMT1PRMT6CARM1
SCHEMBL19432337 0.81 PRMT1 (0.33) PRMT1PRMT6CARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190077795-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2019-03-14 — — US disclosed
US-20170283400-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077795-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 PRMT1 1/4885PRMT6 4/4885CARM1 12/4885
US-20170283400-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 PRMT1 1/4885PRMT6 4/4885CARM1 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback